Peripheral blood leukocyte populations and urinary neopterin during chemotherapy in patients with breast cancer
Králíčková Pavlína,
Vokurková Doris,
Haviger Jiří,
Řezáčová Vladimíra,
Solichová Dagmar,
Krčmová Lenka Kujovská,
Melichar Bohuslav,
Havlík Roman
Affiliations
Králíčková Pavlína
Institute of Clinical Immunology and Allergy, Charles University Medical School and Teaching Hospital, Sokolská 581, 500 05 Hradec Králové, Czech Republic
Vokurková Doris
Institute of Clinical Immunology and Allergy, Charles University Medical School and Teaching Hospital, Sokolská 581, 500 05 Hradec Králové, Czech Republic
Haviger Jiří
Department of Informatics and Quantitative Methods, Faculty of Informatics and Management, University of Hradec Králové, Rokitanskeho 62, 500 03 Hradec Králové, Czech Republic
Řezáčová Vladimíra
Institute of Clinical Immunology and Allergy, Charles University Medical School and Teaching Hospital, Sokolská 581, 500 05 Hradec Králové, Czech Republic
Solichová Dagmar
Third Department of Medicine, Gerontology and Metabolic Care, University Hospital, Sokolská 581, 500 05 Hradec Králové, Czech Republic
Krčmová Lenka Kujovská
Third Department of Medicine, Gerontology and Metabolic Care, University Hospital, Sokolská 581, 500 05 Hradec Králové, Czech Republic
Melichar Bohuslav
Fourth Department of Medicine, Hematology, Sokolská 581, 500 05 Hradec Králové, Czech Republic
Havlík Roman
First Department of Surgery, Palacký University Medical School and Teaching Hospital, I.P. Pavlova 185/6, 779 00 Olomouc, Czech Republic
The aim of the present study was to investigate serial changes in urinary neopterin and the populations of peripheral blood lymphocytes in breast cancer patients treated with primary chemotherapy. Thirty patients with breast cancer, including 20 patients undergoing primary chemotherapy treated with the combination of doxorubicin and cyclophosphamide with sequential administration of paclitaxel-based therapy (cohort A), and 10 patients presenting for first-line therapy of metastatic disease and treated with the combination of bevacizumab, taxane and carboplatin (cohort M) were studied. Healthy female blood donors served as control group. Significant differences were observed in baseline relative and absolute counts of peripheral blood lymphocyte subpopulations between both patient cohorts and controls. Significant changes of peripheral blood lymphocyte subpopulations were also observed during the course of chemotherapy. However, no significant changes of urinary neopterin concentrations and no correlation between urinary neopterin and peripheral blood lymphocyte counts were observed. In conclusion, present data demonstrate the presence of significant differences in peripheral blood leukocyte phenotype in breast cancer patients even before the start of primary chemotherapy. Significant changes were observed during the course of chemotherapy.
